Cerebrolysin

Cerebrolysin[1]
Clinical data
Other namesFPF-1070
AHFS/Drugs.com[2]
Identifiers
CAS Number
DrugBank
UNII

Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).[3][4] Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia.

Cerebrolysin has been studied for potential treatment of several neurodegenerative diseases, with only preliminary research, as of 2023.[4] No clear benefit in the treatment of acute stroke has been found, and an increased rate of spontaneous adverse effects requiring hospitalization is reported.[4] Some positive effects have been reported when cerebrolysin is used to treat vascular dementia.[5]

  1. ^ "Cerebrolysin". Unterach, Austria: Ever Pharma. 2024. Retrieved 10 July 2024.
  2. ^ "Cerebrolysin (International)". Drugs.com. 2024. Retrieved 10 July 2024.
  3. ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". Ageing and Dementia. Journal of Neural Transmission. Supplementa. Vol. 53. pp. 289–98. doi:10.1007/978-3-7091-6467-9_25. ISBN 978-3-211-83114-4. PMID 9700665.
  4. ^ a b c Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K, et al. (Cochrane Stroke Group) (October 2023). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 2023 (10): CD007026. doi:10.1002/14651858.CD007026.pub7. PMC 10565895. PMID 37818733.
  5. ^ Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L (November 2019). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008900.pub3. PMC 6844361. PMID 31710397.